

S2 Table. Patients and treatment characteristics per treatment decade

	2000-2009 (n=51)	2010-2018 (n=111)	p-value
Age (yr)			0.738
≥ 10	17 (33.3)	40 (36.0)	
Sex			0.995
Male	28 (54.9)	61 (55.0)	
Female	23 (45.1)	50 (45.0)	
Performance status			0.574
< 80	26 (52.0)	63 (56.8)	
≥ 80	24 (48.0)	48 (43.2)	
MRI features			
Extrapontine extension	36 (70.6)	88 (80.0)	0.187
Enhancement	35 (70.0)	68 (62.4)	0.351
Infiltrative margin	28 (56.0)	66 (59.5)	0.680
Cyst or necrosis	18 (35.3)	43 (38.7)	0.674
Hydrocephalus	6 (11.8)	17 (15.3)	0.548
WHO grade			0.259
Grade 2	0	4 (11.8)	
Grade 3	5 (50.0)	9 (26.5)	
Grade 4	5 (50.0)	21 (61.8)	
Surgery	29 (21.6)	8 (29.6)	0.368
RT modality			< 0.001
2D	8 (15.7)	0	
3D-CRT	34 (66.7)	29 (26.1)	
IMRT	5 (9.8)	64 (57.7)	
Proton	4 (7.8)	18 (16.2)	
CCRT	25 (49.0)	53 (47.7)	0.880
Adj. chemotherapy	20 (39.2)	38 (34.2)	0.539
Salvage treatment	13 (27.1)	36 (42.4)	0.080
Post-RT necrosis			0.622
No or decreased	23 (50.0)	56 (54.4)	
Increased	23 (50.0)	47 (45.6)	
Imaging response after RT			0.641
CR	2 (4.0)	2 (1.8)	

PR	25 (50.0)	47 (42.7)
SD	13 (26.0)	36 (32.7)
PD	10 (20.0)	25 (22.7)

Values are presented as number (%). 2D, 2-dimensional; 3D-CRT, 3-dimensional conformal radiotherapy; Adj., adjuvant; CCRT, concurrent chemoradiotherapy; CR, complete response; IMRT, intensity-modulated radiotherapy; MRI, magnetic resonance image; PD, progressive disease; PR, partial response; RT, radiotherapy; SD, stable disease; WHO, World Health Organization.